News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2014

First Patients Enrolled in Epigenomics’ Epi proColon® ADMIT Study

17.12.2014 | 141217_Press_release_Epigenomics_AG_First_Patients_in_ADMIT Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that first patients have been enrolled into its ADMIT trial (ADherence to Minimally Invasive Testing) for its noninvasive blood-based test for colorectal cancer (CRC) screening, Epi proColon®.

Read more

Epigenomics to present at the Oppenheimer 25th Annual Healthcare Conference

10.12.2014 | Press_release_Epigenomics_AG_10_December_2014_01 Berlin (Germany) and Germantown, MD (U.S.A.), December 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that CEO/CFO Dr. Thomas Taapken will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014, at 9.45 a.m. EST in room […]

Read more

Epigenomics and BioChain Announce Approval of Epi proColon® in China

08.12.2014 | Press_release_Epigenomics_AG_BioChain_Approval_EPC_in_China Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.) and Beijing (China) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics company in cancer and genetic testing in China and the U.S.A., announced today that the China Food and Drug Administration […]

Read more

Ad hoc: Epigenomics and BioChain Announce Approval of Epi proColon® in China

PDF 145 KB   Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics company in cancer and genetic testing in China and the U.S.A., announced today that the China Food and Drug Administration […]

Read more

Epigenomics AG Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights

11.11.2014 | 141111_Press_release_Epigenomics_AG_Q3_2014_results Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the third quarter and the nine months 2014 ending September 30.

Read more

Epigenomics’ strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon® in the United States

03.11.2014 | 141103_Press_release_Epigenomics_AG_Polymdeco Berlin (Germany) and Germantown, MD (USA) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that Polymedco, Inc., a leading provider of colorectal cancer tests in North America, reiterates its commitment to support Epi proColon® in the United States. Epi proColon® is Epigenomics’ convenient blood-based […]

Read more